TITLE

Interferon-β-1b: In Newly Emerging Multiple Sclerosis

AUTHOR(S)
McKeage, Kate
PUB. DATE
July 2008
SOURCE
CNS Drugs;2008, Vol. 22 Issue 9, p787
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
▴ The mechanism of action of interferon-β-1b in multiple sclerosis (MS) is not clearly understood, but is thought to involve immunoregulatory activities, including enhancing the suppressor activity of peripheral blood mononuclear cells. ▴ In the planned 3-year analysis of the BENEFIT study in patients with a single clinical event suggestive of MS, the relative risk of clinically definite (CD) MS was reduced by 41% in those receiving interferon-β-1b 250 μg every other day for 3 years (early-treatment group) compared with patients who were initially randomized to placebo then switched to interferon-β-1b 250 μg every other day at the end of 2 years or at the onset of CDMS (delayed-treatment group) [p < 0.01]. ▴ The relative risk of confirmed progression of the expanded disability status scale (EDSS) was reduced by 40% in the early-treatment group compared with the delayed-treatment group over 3 years (p < 0.05). ▴ At the end of the 2-year, randomized, placebocontrolled period of the BENEFIT study, the risk of developing CDMS (p < 0.0001) and McDonald-defined MS (p < 0.00001) was significantly lower in the interferon-β-1b group than in the placebo group, and in the magnetic resonance imaging analysis, fewer newly active lesions developed in the interferon-β-1b group (p < 0.001). ▴ Interferon-β-1b was generally well tolerated. In the 3-year BENEFIT study, neutralizing activity, which was reported in about one-third of the early-treatment group, had no effect on outcome.
ACCESSION #
35282122

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics